AIDS
MCID: ACQ007
MIFTS: 60

Acquired Immunodeficiency Syndrome (AIDS)

Categories: Blood diseases, Cancer diseases, Immune diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Acquired Immunodeficiency Syndrome

MalaCards integrated aliases for Acquired Immunodeficiency Syndrome:

Name: Acquired Immunodeficiency Syndrome 12 43 15 71
Acquired Immune Deficiency Syndrome 12 3 15
Aids 12 47
Acquired Immune Deficiency 12
Acquired Immunodeficiency 58

Classifications:

Orphanet: 58  
Rare immunological diseases


External Ids:

Disease Ontology 12 DOID:635
MeSH 43 D000163
NCIt 49 C2851
SNOMED-CT 67 62479008
ICD10 32 B20
UMLS via Orphanet 72 C0001175
Orphanet 58 ORPHA310050
UMLS 71 C0001175

Summaries for Acquired Immunodeficiency Syndrome

CDC : 3 HIV is a virus spread through certain body fluids that attacks the body's immune system, specifically the CD4 cells, often called T cells. Over time, HIV can destroy so many of these cells that the body can't fight off infections and disease. These special cells help the immune system fight off infections. Untreated, HIV reduces the number of CD4 cells (T cells) in the body. This damage to the immune system makes it harder and harder for the body to fight off infections and some other diseases. Opportunistic infections or cancers take advantage of a very weak immune system and signal that the person has AIDS. Learn more about the stages of HIV and how to know whether you have HIV.

MalaCards based summary : Acquired Immunodeficiency Syndrome, also known as acquired immune deficiency syndrome, is related to human immunodeficiency virus type 1 and ascaris lumbricoides infection. An important gene associated with Acquired Immunodeficiency Syndrome is RN7SK (RNA Component Of 7SK Nuclear Ribonucleoprotein), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Oseltamivir have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and brain, and related phenotypes are cellular and endocrine/exocrine gland

Disease Ontology : 12 A Human immunodeficiency virus infectious disease that results in reduction in the numbers of CD4-bearing helper T cells below 200 per microliter of blood or 14% of all lymphocytes thereby rendering the subject highly vulnerable to life-threatening infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. Opportunistic infections are common in people with AIDS.

Related Diseases for Acquired Immunodeficiency Syndrome

Diseases related to Acquired Immunodeficiency Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3061)
# Related Disease Score Top Affiliating Genes
1 human immunodeficiency virus type 1 34.0 TNF ITIH4 IL2 IL10 IFNG CD4
2 ascaris lumbricoides infection 32.9 IL6 IL10 IFNG
3 guillain-barre syndrome 32.9 TNF CD40LG ALB
4 granulomatosis with polyangiitis 32.9 TNF CD40LG CD4 CCR5
5 immune deficiency disease 32.7 TNF ITIH4 IL6 IL2 IL10 IFNG
6 kaposi sarcoma 32.7 MYC IL6 IFNA1 CSF2 CCR5
7 chronic mucocutaneous candidiasis 32.3 TNF IL6 IL10 IFNG IFNA1 CSF2
8 toxoplasmosis 32.2 TNF IL6 IL10 IFNG CD40LG CCR5
9 histoplasmosis 32.2 TNF IFNG CD40LG CD4
10 cryptococcosis 32.2 TNF IL10 IFNG CSF2 CD4
11 cytomegalovirus infection 32.1 TNF IL6 B2M
12 cryptococcal meningitis 32.1 IFNG CSF2 CD4
13 cytomegalovirus retinitis 32.1 TNF IL10 IFNG CSF2 CD40LG CD4
14 cryptosporidiosis 32.0 IFNG CD40LG CD4
15 pneumocystosis 31.9 TNF IL6 CD40LG CD4 CCR5 ALB
16 lymphoma 31.9 MYC IL6 IL2 IL10 CSF2 CD40LG
17 candidiasis 31.9 TNF IL6 IL2 IL10 IFNG CSF2
18 progressive multifocal leukoencephalopathy 31.9 TNF IL2 CD40LG CD4
19 esophagitis 31.9 TNF IL6 IL10
20 encephalitis 31.9 TNF ITIH4 IL6 IL10 IFNA1 CD40LG
21 neuroretinitis 31.8 CD40LG CD4
22 vasculitis 31.8 TNF IL6 IL10 CD40LG
23 diarrhea 31.8 TNF IL6 IL2 IL10 IFNG IFNA1
24 central nervous system lymphoma 31.8 TNF MYC IL6 IL2 IL10
25 lymphopenia 31.8 IL6 IL2 IL10 IFNG B2M
26 respiratory failure 31.7 TNF IL6 IL10 CD40LG CD4 ALB
27 aspergillosis 31.7 TNF IL6 IL10 IFNG CSF2
28 retinal detachment 31.7 TNF IL6 IL10 IFNG
29 neutropenia 31.6 TNF IL6 IL2 IL10 IFNG IFNA1
30 aids dementia complex 31.6 TNF ITIH4 B2M
31 uveitis 31.6 TNF IL6 IL2 IL10 IFNG CCR5
32 meningitis 31.6 TNF IL6 IL2 IL10 IFNG CSF2
33 visceral leishmaniasis 31.6 TNF IL2 IL10 IFNG ALB
34 pericardial effusion 31.6 IL6 CD40LG CD4 ALB
35 pulmonary tuberculosis 31.6 TNF IL6 IL2 IL10 IFNG ALB
36 myocarditis 31.6 TNF IL6 IL2 IL10 IFNG IFNA1
37 colitis 31.6 TNF IL6 IL2 IL10 IFNG
38 pancytopenia 31.6 IL6 IFNG CSF2 CD40LG CD4 ALB
39 mycobacterium tuberculosis 1 31.6 TNF IL10 IFNG CD4
40 retinitis pigmentosa 31.6 TNF NEAT1 MYC IL6 IL2 IL10
41 bacterial infectious disease 31.6 TNF ITIH4 IL6 IL10 IFNG CSF2
42 chickenpox 31.6 TNF IL6 IL2 IL10 IFNG IFNA1
43 extrapulmonary tuberculosis 31.5 TNF IL10 IFNG CD4 ALB
44 syphilis 31.5 TNF IL6 IFNG CD40LG CD4 CCR5
45 lymphadenitis 31.5 TNF IL10 IFNG CD4
46 myelitis 31.5 TNF IL6 IL10 CD40LG
47 pericarditis 31.5 TNF IL6 IFNG CD40LG CD4 ALB
48 bacterial pneumonia 31.5 TNF IL6 IL10 CD40LG CD4 ALB
49 cholangitis 31.5 TNF IL6 IL2 IL10 CD40LG CCR5
50 purpura 31.5 TNF IL6 IL10 IFNG CD40LG

Graphical network of the top 20 diseases related to Acquired Immunodeficiency Syndrome:



Diseases related to Acquired Immunodeficiency Syndrome

Symptoms & Phenotypes for Acquired Immunodeficiency Syndrome

MGI Mouse Phenotypes related to Acquired Immunodeficiency Syndrome:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 ALB B2M CCR5 CD38 CD4 CD40LG
2 endocrine/exocrine gland MP:0005379 10.25 ALB B2M CD38 CD4 CD40LG CSF2
3 cardiovascular system MP:0005385 10.24 ALB B2M CCR5 CD40LG CSF2 IFNG
4 hematopoietic system MP:0005397 10.18 B2M CCR5 CD38 CD4 CD40LG CSF2
5 homeostasis/metabolism MP:0005376 10.18 ALB B2M CCR5 CD38 CD4 CD40LG
6 digestive/alimentary MP:0005381 10.16 ALB B2M CCR5 CD4 IFNG IL10
7 immune system MP:0005387 10.13 ALB B2M CCR5 CD38 CD4 CD40LG
8 integument MP:0010771 9.91 B2M CD4 CD40LG CSF2 IFNG IL10
9 liver/biliary system MP:0005370 9.85 ALB B2M CCR5 IFNG IL10 IL2
10 neoplasm MP:0002006 9.7 ALB B2M CCR5 CSF2 IFNG IL10
11 reproductive system MP:0005389 9.36 B2M CCR5 CD40LG CSF2 IFNG IL10

Drugs & Therapeutics for Acquired Immunodeficiency Syndrome

Drugs for Acquired Immunodeficiency Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 950)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
3
Sodium Tetradecyl Sulfate Approved, Investigational Phase 4 1191-50-0, 139-88-8 5248 14492
4
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
5
Didanosine Approved Phase 4 69655-05-6 50599
6
Fosamprenavir Approved Phase 4 226700-79-4 131536
7
Indinavir Approved Phase 4 150378-17-9 5362440
8
leucovorin Approved Phase 4 58-05-9 6006 143
9
Sulfamethoxazole Approved Phase 4 723-46-6 5329
10
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
11
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
12
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
13
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
14
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
15
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
16
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
17
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
18
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
19
Polyestradiol phosphate Approved Phase 4 28014-46-2
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
22
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
23
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
24
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
25
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
26
Acetaminophen Approved Phase 4 103-90-2 1983
27
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
28
Ferrous fumarate Approved Phase 4 141-01-5
29
Ledipasvir Approved Phase 4 1256388-51-8 67505836
30
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
31
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
32
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
33
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
34
Copper Approved, Investigational Phase 4 7440-50-8 27099
35
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
36
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
37
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
38
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
39
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
40
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
41
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
42
Desipramine Approved, Investigational Phase 4 50-47-5 2995
43
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
44
Lumefantrine Approved Phase 4 82186-77-4 6437380
45
Oxandrolone Approved, Investigational Phase 4 53-39-4 5878
46
Hexetidine Approved, Investigational Phase 4 141-94-6
47
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
48
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
49
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
50
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468

Interventional clinical trials:

(show top 50) (show all 5003)
# Name Status NCT ID Phase Drugs
1 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
2 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
3 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B Unknown status NCT03120494 Phase 4 Emtricitabine and Tenofovir
4 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
5 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
6 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
7 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
8 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
9 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
10 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
11 Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C Unknown status NCT01147107 Phase 4 Raltegravir;Efavirenz
12 The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness Unknown status NCT01264510 Phase 4
13 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir(RAL)in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
14 Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations Unknown status NCT01347294 Phase 4 Bleomycin;Fibrovein;Bleomycin + Fibrovein
15 Treating HIV-infected Elite Controllers as a Model of HIV Remission Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
16 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
17 Curing HCV in Incarcerated Patients Unknown status NCT03018353 Phase 4 Patients receiving Sof/Vel (Epclusa) and Navigation services
18 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
19 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
20 Is Dual Therapy as Effective as Triple Therapy Regarding CD4+/CD8+ Ratio Recovery and Improvement of Immune Activation and Inflammation in HIV-infected Patients With Consistent Plasma Viral Load Suppression (Tridual) Unknown status NCT03447873 Phase 4 Continue with triple therapy;Switch to DTG + 3TC;Switch to DRV/cobicistat + 3TC
21 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
22 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
23 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
24 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
25 Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort Completed NCT00618176 Phase 4 Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP);Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP);Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)
26 Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation Completed NCT03314064 Phase 4 Dolutegravir 50 mg
27 Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy Completed NCT01285050 Phase 4 Antiretroviral therapy (ART);raltegravir;Emtricitabine and tenofovir disoproxil fumarate
28 An Open-Label Randomized Pharmacokinetic/Pharmacodynamic Study of Mycobutin (Rifabutin) or Rifabutin in Combination With Myambutol (Ethambutol) for Prophylaxis of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts <= 100 Cells/mm3 Completed NCT00002343 Phase 4 Ethambutol hydrochloride;Rifabutin
29 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
30 A Randomised Comparator Study to Assess the Relative Efficacy of Genotypic Versus Virtual Phenotypic Resistance Tests in Treatment Experienced Patients With HIV Infection for Whom a Change in Therapy is Indicated Completed NCT00262717 Phase 4
31 An Open-label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options Completed NCT00240552 Phase 4 fosamprenavir;Telzir®
32 Phase IV, Non Randomized Study in ARV Experienced Patients Under Switch Therapy With Kaletra Completed NCT00648999 Phase 4 lopinavir/ritonavir
33 An Open-label Single Oral Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-0518 1200 mg (600 mg Tablet × 2) in Healthy Japanese Male Participants Completed NCT03667547 Phase 4 Raltegravir
34 Gradual Initiation of Trimethoprim/Sulfamethoxazole as Primary Pneumocystis Carinii Pneumonia Prophylaxis Completed NCT00000816 Phase 4 Sulfamethoxazole-Trimethoprim
35 Defining the Rectal Mucosa in Men Who Have Sex With Men at Risk of HIV Infection Completed NCT02401230 Phase 4 Truvada
36 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
37 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
38 Continuous Versus Cyclic Use of Combined Oral Contraceptive Pills Completed NCT00570440 Phase 4 Oral contraceptives--ethinyl estradiol, levonorgestrel
39 Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-infected Ugandan Adults Completed NCT01025830 Phase 4 Triomune;Zerit/Epivir/Viramune
40 Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence Among Black Men Who Have Sex With Men (BMSM) in Three U.S. Cities Completed NCT01808352 Phase 4 FTC/TDF
41 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
42 An Open-Label Study of Nevirapine Plus Combivir® (ZDV+3TC) Treatment in Women Who Have Previously Received a Nevirapine Regimen for the Prevention of Mother to Child Transmission (pMTCT) of HIV-1. Completed NCT00144157 Phase 4 Nevirapine;Zidovudine;3TC
43 Pharmacokinetics of Lopinavir Crushed Versus Whole Tablets in Pediatric Patients Completed NCT00810108 Phase 4 lopinavir/ritonavir (Kaletra®) tablets
44 Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection Completed NCT00801879 Phase 4 Mupirocin calcium ointment, 2%;Placebo ointment
45 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
46 Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL Completed NCT00342355 Phase 4 Zidovudine;Stavudine;Didanosine;Lamivudine;Efavirenz;Lopinavir/Ritonavir
47 Prospective Epidemiological Study of the Prevalence of HLAB*5701 in HIV-1 Infected Patients Completed NCT00441688 Phase 4 GI265235
48 Safety and Immunogenicity of Cervarix™ in Human Immunodeficiency Virus Infected Females Completed NCT01031069 Phase 4
49 Phase IV Study on the Safety and Efficacy of Megace Oral Suspension in HIV-Positive Females Completed NCT00002345 Phase 4 Megestrol acetate
50 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana Completed NCT01086878 Phase 4 cotrimoxazole

Search NIH Clinical Center for Acquired Immunodeficiency Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


abacavir
abacavir sulfate
Amprenavir
Delavirdine
Delavirdine Mesylate
Didanosine
efavirenz
enfuvirtide
Immunoglobulins, Intravenous
Indinavir
Indinavir Sulfate
Lamivudine
lopinavir
Nelfinavir
Nelfinavir Mesylate
Nevirapine
Ritonavir
Saquinavir
saquinavir mesylate
Stavudine
Tenofovir
tenofovir alafenamide fumarate
Tenofovir disoproxil fumarate
Zalcitabine
Zidovudine

Cochrane evidence based reviews: acquired immunodeficiency syndrome

Genetic Tests for Acquired Immunodeficiency Syndrome

Anatomical Context for Acquired Immunodeficiency Syndrome

MalaCards organs/tissues related to Acquired Immunodeficiency Syndrome:

40
Testes, T Cells, Brain, Bone, Breast, Lung, Liver

Publications for Acquired Immunodeficiency Syndrome

Articles related to Acquired Immunodeficiency Syndrome:

(show top 50) (show all 20943)
# Title Authors PMID Year
1
CD4 binding loop responsible for the neutralization of human monoclonal neutralizing antibody Y498. 61
32413370 2020
2
Advances in HIV diagnosis and monitoring. 61
32308063 2020
3
Development of a pseudovirus assay and evaluation to screen natural products for inhibition of HIV-1 subtype C reverse transcriptase. 61
32360797 2020
4
Successful implementation of intestinal resection and anastomosis in non-human primates suggests the possibility of longitudinal intestinal research. 61
32521575 2020
5
Excision and Primary Reanastomosis of the Anterior Inferior Cerebellar Artery for Treatment of a Ruptured Mycotic Aneurysm: 2-Dimensional Operative Video. 61
31603238 2020
6
An exploration of recorded otological manifestations in South African children with HIV/AIDS: A pilot study. 61
32097775 2020
7
CHARACTERISTICS OF GRAVES DISEASE IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY. 61
31968184 2020
8
Perioperative Antiretroviral Regimen for HIV/AIDS Patients Who Underwent Abdominal Surgery. 61
32020326 2020
9
Modeling Viral Suppression, Viral Rebound and State-Specific Duration of HIV Patients with CD4 Count Adjustment: Parametric Multistate Frailty Model Approach. 61
32318999 2020
10
A biophysical perspective on receptor-mediated virus entry with a focus on HIV. 61
31863725 2020
11
Spatial-temporal characteristics of AIDS incidences in Mainland China. 61
32543772 2020
12
Disseminated Nocardia beijingensis Masquerading as Pulmonary Tuberculosis in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome. 61
32548208 2020
13
Perinatal transmission in Human Immunodeficiency Virus infection: a cross-sectional study from a tertiary care center in North India. 61
32487787 2020
14
Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV. 61
32545407 2020
15
Recent updates on drug resistance in Mycobacterium tuberculosis. 61
31595643 2020
16
A Systematic Review and Meta-Analysis of Interventions for Orphans and Vulnerable Children Affected by HIV/AIDS Worldwide. 61
32525205 2020
17
N-p-Tosyl-L-phenylalanine chloromethyl ketone (TPCK) inhibits HIV-1 by suppressing the activity of viral protease. 61
32446362 2020
18
CRISPR Genome Editing Technology and its Application in Genetic Diseases: A Review. 61
32564746 2020
19
Tonsillar Kaposi sarcoma in a renal transplant patient. 61
32495980 2020
20
Epidemiology and Etiology of Leukemia and Lymphoma. 61
31727680 2020
21
Homelessness among an inpatient HIV-positive cohort at a tertiary care hospital in central London. 61
32448076 2020
22
The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro. 61
32562524 2020
23
Update on T cells in the virally infected brain: friends and foes. 61
32304440 2020
24
Preclinical Development and Clinical-Scale Manufacturing of HIV Gag-Specific, LentivirusModified CD4 T Cells for HIV Functional Cure. 61
32462053 2020
25
Timing of antiretroviral therapy for HIV-infected patients with moderate to severe Pneumocystis pneumonia: study protocol for a multi-centre prospective randomised controlled trial. 61
32571429 2020
26
Candidiasis and Mechanisms of Antifungal Resistance. 61
32526921 2020
27
A cross-sectional study on caregivers' perspective of the quality of life and adherence of paediatric HIV patients to highly active antiretroviral therapy. 61
32517722 2020
28
Prediction and validation of HIV-1 gp41 ecto-transmembrane domain post-fusion trimeric structure using molecular modeling. 61
31232193 2020
29
HIV infection confers distinct mechanisms in severe drug eruption: Endogenous virus activation with aberrant Th2/Th1 and CD8+ T cells function. 61
31991490 2020
30
Nodular pulmonary deposition disease in a patient with the acquired immunodeficiency syndrome: a case report. 61
32498712 2020
31
Epidemiologic and clinical findings of children with acquired immunodeficiency syndrome in four provinces of Iran. 61
31410715 2020
32
Associations of Viral Seroreactivity with AIDS-Related Non-Hodgkin Lymphoma. 61
31789046 2020
33
Depressive Disorders in HIV/AIDS: A Clinically Focused Narrative Review. 61
32251069 2020
34
Stroke-Associated Pneumonia: A Retrospective Study of Risk Factors and Outcomes. 61
32358460 2020
35
Epstein-Barr virus associated hepatic smooth muscle tumor in a patient with acquired immunodeficiency syndrome: A case report. 61
32358363 2020
36
Evolution of virulence-related phenotypes of Sporothrix brasiliensis isolates from patients with chronic sporotrichosis and acquired immunodeficiency syndrome. 61
32440844 2020
37
The Potential Impact of One-Time Routine HIV Screening on Prevention and Clinical Outcomes in the United States: A Model-Based Analysis. 61
32044862 2020
38
Abnormal Dispersion of Ventricular Repolarization as a Risk Factor in Patients with Human Immunodeficiency Virus: Tp-e interval, Tp-e/QTc ratio. 61
32422636 2020
39
Can environmental determinants explain Nontuberculous Mycobacteria geographic incidence? 61
31882260 2020
40
Not an epidemic, but a global problem: the authorities' construction of HIV/AIDS in Russia. 61
32481246 2020
41
Impact of ART-induced viral suppression on the HIV epidemic in Italy. 61
31162541 2020
42
Same same but different - Antiviral factors interfering with the infectivity of HIV particles. 61
32450247 2020
43
Unrecognized HIV infection in asymptomatic volunteer blood donors at district Peshawar, Khyber Pakhtunkhwa, Pakistan. 61
32454980 2020
44
A case of acanthosis nigricans in a HIV-infected patient. 61
32434484 2020
45
Utility of Ultra-Widefield Retinal Imaging in the Follow-up and Management of Patients with Cytomegalovirus Retinitis. 61
31268742 2020
46
Intravenous Drug Use History Is Not Associated with Poorer Outcomes After Arteriovenous Access Creation. 61
32445833 2020
47
Multiplier method estimates of the population of men who have sex with men: the effect of privacy protection. 61
30806667 2020
48
Escalating and sustained immunovirological dissociation among antiretroviral drug-experienced perinatally human immunodeficiency virus-1-infected children and adolescents living in the Central African Republic: A STROBE-compliant study. 61
32481261 2020
49
CD8+ T-cell encephalitis mimicking PRES in AIDS: a case report. 61
32397957 2020
50
Small Conformational Changes Underlie Evolution of Resistance to NNRTI in HIV Reverse Transcriptase. 61
32348721 2020

Variations for Acquired Immunodeficiency Syndrome

Expression for Acquired Immunodeficiency Syndrome

Search GEO for disease gene expression data for Acquired Immunodeficiency Syndrome.

Pathways for Acquired Immunodeficiency Syndrome

Pathways related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TNF MYC IL6 IL2 IL10 IFNG
2
Show member pathways
13.85 TNF MYC IL6 IL2 IL10 CSF2
3
Show member pathways
13.73 TNF MYC IL6 IL2 IL10 IFNG
4
Show member pathways
13.57 TNF MYC IL6 IL2 IL10 IFNG
5
Show member pathways
13.46 TNF IL6 IL2 IL10 CSF2 CD40LG
6
Show member pathways
13.35 TNF IL6 IL2 IL10 CSF2 CD40LG
7
Show member pathways
13.26 TNF MYC IL6 IL2 IL10 IFNG
8
Show member pathways
13.11 TNF MYC IL6 IL2 IL10 IFNG
9
Show member pathways
12.99 TNF MYC IL6 IFNA1 CSF2 CD4
10
Show member pathways
12.89 TNF MYC IL6 IL2 IFNG IFNA1
11 12.82 TNF IL6 IFNG IFNA1 B2M
12
Show member pathways
12.8 TNF IL6 IL2 IL10 IFNG IFNA1
13
Show member pathways
12.71 TNF IFNG CD40LG CD4 CCR5
14
Show member pathways
12.7 TNF IL2 IL10 IFNG CD40LG CD4
15
Show member pathways
12.67 TNF MYC IL6 IL2 IL10 IFNG
16
Show member pathways
12.64 TNF MYC IL6 IL2 IL10 IFNG
17
Show member pathways
12.57 TNF IL2 IFNG IFNA1 CSF2
18 12.55 TNF IL2 IL10 IFNG IFNA1 CD40LG
19
Show member pathways
12.48 MYC IL6 IL2 IL10 IFNG IFNA1
20
Show member pathways
12.45 TNF IL6 IL2 IL10 IFNG CSF2
21
Show member pathways
12.4 TNF IL6 IL2 IL10 CCR5
22
Show member pathways
12.4 TNF IL6 IL2 IFNG ALB
23 12.39 TNF MYC IL6 IL2 CSF2 CD4
24
Show member pathways
12.36 TNF IL6 IFNG CSF2
25
Show member pathways
12.33 TNF IL10 IFNG CD40LG CCR5
26
Show member pathways
12.33 TNF MYC IL6 IL2 IL10 IFNG
27 12.31 TNF IL6 IL10 IFNG IFNA1
28
Show member pathways
12.26 TNF IL6 IL2 IL10
29 12.23 TNF MYC IL6 IFNG
30 12.1 TNF MYC IL6 IL2 IFNG
31 12.07 TNF IL6 IL2 IL10
32
Show member pathways
12.07 IL2 IFNG CD4 CCR5 B2M
33 12.05 TNF MYC IL6 IL10
34 12.01 TNF IL6 IL10 IFNG CSF2
35
Show member pathways
12 TNF IL6 IL2 IL10 IFNG CD4
36 11.99 TNF IL6 CSF2 CD4 CD38
37 11.95 TNF IL6 IFNG CSF2
38 11.88 IL6 IL2 IFNG CSF2
39